 Daniel Pollyea
Concepts (462)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 105 | 2024 | 536 | 25.240 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 32 | 2024 | 172 | 8.310 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 43 | 2024 | 1361 | 7.400 |
Why?
| | Myelodysplastic Syndromes | 28 | 2023 | 119 | 6.740 |
Why?
| | Sulfonamides | 27 | 2024 | 445 | 6.540 |
Why?
| | Azacitidine | 22 | 2024 | 129 | 6.000 |
Why?
| | Mutation | 33 | 2024 | 3353 | 3.190 |
Why?
| | Isocitrate Dehydrogenase | 13 | 2022 | 38 | 3.160 |
Why?
| | Hematologic Neoplasms | 10 | 2023 | 136 | 3.040 |
Why?
| | Antineoplastic Agents | 23 | 2023 | 1897 | 3.000 |
Why?
| | Neoplasm, Residual | 7 | 2024 | 104 | 2.440 |
Why?
| | Neoplastic Stem Cells | 12 | 2023 | 334 | 2.240 |
Why?
| | Hematopoietic Stem Cell Transplantation | 15 | 2023 | 525 | 2.170 |
Why?
| | Triazines | 7 | 2021 | 36 | 2.070 |
Why?
| | Aminopyridines | 7 | 2021 | 81 | 2.010 |
Why?
| | Graft vs Host Disease | 8 | 2022 | 215 | 1.750 |
Why?
| | Remission Induction | 15 | 2021 | 233 | 1.640 |
Why?
| | RNA Splicing Factors | 3 | 2020 | 49 | 1.520 |
Why?
| | Humans | 147 | 2024 | 114925 | 1.410 |
Why?
| | Phosphoproteins | 3 | 2020 | 299 | 1.340 |
Why?
| | Cytarabine | 8 | 2022 | 52 | 1.300 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2020 | 863 | 1.280 |
Why?
| | Aged | 54 | 2024 | 19120 | 1.250 |
Why?
| | Leukemia | 4 | 2023 | 210 | 1.190 |
Why?
| | Prognosis | 24 | 2024 | 3344 | 1.140 |
Why?
| | Aged, 80 and over | 29 | 2024 | 6363 | 1.140 |
Why?
| | Salvage Therapy | 5 | 2023 | 127 | 1.080 |
Why?
| | Clonal Evolution | 2 | 2017 | 27 | 1.050 |
Why?
| | Nuclear Proteins | 5 | 2018 | 593 | 0.960 |
Why?
| | Treatment Outcome | 29 | 2024 | 9105 | 0.950 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 57 | 0.950 |
Why?
| | fms-Like Tyrosine Kinase 3 | 4 | 2017 | 43 | 0.940 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 258 | 0.930 |
Why?
| | Carrier Proteins | 3 | 2017 | 696 | 0.880 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2020 | 642 | 0.870 |
Why?
| | Molecular Targeted Therapy | 6 | 2020 | 347 | 0.860 |
Why?
| | Leukemia, Neutrophilic, Chronic | 3 | 2019 | 5 | 0.850 |
Why?
| | Thrombocytopenia | 2 | 2023 | 177 | 0.820 |
Why?
| | Spliceosomes | 2 | 2020 | 38 | 0.820 |
Why?
| | Dancing | 1 | 2022 | 13 | 0.820 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2020 | 95 | 0.800 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2018 | 213 | 0.790 |
Why?
| | Anemia | 2 | 2020 | 144 | 0.790 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 752 | 0.790 |
Why?
| | Middle Aged | 41 | 2024 | 26801 | 0.760 |
Why?
| | Febrile Neutropenia | 1 | 2020 | 3 | 0.740 |
Why?
| | Splicing Factor U2AF | 2 | 2023 | 16 | 0.710 |
Why?
| | Serine-Arginine Splicing Factors | 2 | 2019 | 18 | 0.690 |
Why?
| | Receptors, Colony-Stimulating Factor | 2 | 2017 | 5 | 0.680 |
Why?
| | DNA Methylation | 3 | 2019 | 496 | 0.670 |
Why?
| | Transplantation Conditioning | 8 | 2022 | 152 | 0.660 |
Why?
| | Phenylurea Compounds | 7 | 2020 | 84 | 0.630 |
Why?
| | Male | 50 | 2024 | 55655 | 0.610 |
Why?
| | Female | 55 | 2024 | 59571 | 0.610 |
Why?
| | Stem Cells | 3 | 2020 | 546 | 0.600 |
Why?
| | Staurosporine | 1 | 2017 | 21 | 0.600 |
Why?
| | Benzimidazoles | 6 | 2020 | 138 | 0.580 |
Why?
| | Gene Frequency | 2 | 2017 | 481 | 0.540 |
Why?
| | Recurrence | 9 | 2023 | 937 | 0.540 |
Why?
| | Glycine | 4 | 2021 | 152 | 0.530 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 441 | 0.530 |
Why?
| | Adult | 29 | 2024 | 30604 | 0.530 |
Why?
| | Monocytes | 2 | 2018 | 504 | 0.520 |
Why?
| | Signal Transduction | 9 | 2022 | 4524 | 0.520 |
Why?
| | Skin Neoplasms | 1 | 2023 | 762 | 0.520 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.520 |
Why?
| | Leukocytosis | 1 | 2015 | 35 | 0.520 |
Why?
| | Retrospective Studies | 15 | 2024 | 12543 | 0.510 |
Why?
| | Gene Expression | 1 | 2020 | 1422 | 0.510 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 523 | 0.500 |
Why?
| | Computational Biology | 1 | 2019 | 531 | 0.500 |
Why?
| | Precision Medicine | 1 | 2018 | 339 | 0.490 |
Why?
| | Medical Oncology | 4 | 2023 | 228 | 0.480 |
Why?
| | Pyridines | 5 | 2023 | 425 | 0.480 |
Why?
| | Patient Safety | 1 | 2018 | 278 | 0.480 |
Why?
| | Maximum Tolerated Dose | 5 | 2019 | 184 | 0.470 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 95 | 0.450 |
Why?
| | Hematopoiesis | 4 | 2020 | 172 | 0.450 |
Why?
| | Pyrazoles | 1 | 2017 | 364 | 0.450 |
Why?
| | Neoplasm Proteins | 4 | 2022 | 385 | 0.450 |
Why?
| | Apoptosis | 4 | 2018 | 2371 | 0.440 |
Why?
| | Immunity, Innate | 1 | 2019 | 724 | 0.440 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 1856 | 0.430 |
Why?
| | Germ-Line Mutation | 3 | 2022 | 131 | 0.430 |
Why?
| | Oxidative Phosphorylation | 5 | 2022 | 156 | 0.420 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 40 | 0.420 |
Why?
| | Glutarates | 1 | 2012 | 6 | 0.410 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 26 | 0.400 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2023 | 666 | 0.400 |
Why?
| | Protein Kinase Inhibitors | 9 | 2018 | 796 | 0.400 |
Why?
| | Neoplasms | 4 | 2018 | 2106 | 0.390 |
Why?
| | Follow-Up Studies | 8 | 2020 | 4427 | 0.390 |
Why?
| | RNA Splicing | 4 | 2023 | 245 | 0.390 |
Why?
| | Neutrophils | 2 | 2023 | 1164 | 0.390 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 296 | 0.390 |
Why?
| | United States Food and Drug Administration | 2 | 2022 | 172 | 0.370 |
Why?
| | Survival Rate | 10 | 2020 | 1644 | 0.360 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2017 | 134 | 0.350 |
Why?
| | Rhipicephalus sanguineus | 1 | 2009 | 1 | 0.350 |
Why?
| | Triatoma | 1 | 2009 | 5 | 0.350 |
Why?
| | Wasps | 1 | 2009 | 8 | 0.350 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 13 | 0.340 |
Why?
| | Syncope | 1 | 2009 | 37 | 0.340 |
Why?
| | Cytokines | 4 | 2020 | 1843 | 0.330 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 184 | 0.330 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 23 | 0.320 |
Why?
| | Kaplan-Meier Estimate | 5 | 2020 | 817 | 0.320 |
Why?
| | Mutant Proteins | 2 | 2019 | 95 | 0.320 |
Why?
| | Administration, Oral | 4 | 2018 | 731 | 0.310 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 139 | 0.310 |
Why?
| | Acute Disease | 3 | 2023 | 915 | 0.310 |
Why?
| | Cell Self Renewal | 2 | 2019 | 49 | 0.310 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 611 | 0.310 |
Why?
| | Bone Marrow | 4 | 2017 | 245 | 0.310 |
Why?
| | Young Adult | 13 | 2021 | 10476 | 0.300 |
Why?
| | Transplantation, Homologous | 6 | 2022 | 387 | 0.300 |
Why?
| | Survival Analysis | 6 | 2020 | 1220 | 0.300 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2016 | 49 | 0.290 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 718 | 0.290 |
Why?
| | Anaphylaxis | 1 | 2009 | 148 | 0.280 |
Why?
| | Disease-Free Survival | 5 | 2022 | 623 | 0.280 |
Why?
| | Thrombocythemia, Essential | 2 | 2016 | 6 | 0.270 |
Why?
| | Primary Myelofibrosis | 2 | 2016 | 9 | 0.270 |
Why?
| | Polycythemia Vera | 2 | 2016 | 12 | 0.270 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 934 | 0.270 |
Why?
| | Hematopoietic Stem Cells | 3 | 2022 | 345 | 0.260 |
Why?
| | Cytogenetic Analysis | 2 | 2022 | 29 | 0.250 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1054 | 0.250 |
Why?
| | Animals | 24 | 2023 | 31837 | 0.250 |
Why?
| | Influenza Vaccines | 1 | 2010 | 497 | 0.250 |
Why?
| | DEAD-box RNA Helicases | 2 | 2015 | 56 | 0.250 |
Why?
| | Influenza, Human | 1 | 2010 | 546 | 0.230 |
Why?
| | Stem Cell Transplantation | 3 | 2023 | 149 | 0.230 |
Why?
| | Induction Chemotherapy | 2 | 2021 | 56 | 0.230 |
Why?
| | Allografts | 2 | 2021 | 122 | 0.230 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1270 | 0.230 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1317 | 0.220 |
Why?
| | Mice | 16 | 2023 | 14935 | 0.220 |
Why?
| | Finland | 1 | 2023 | 69 | 0.220 |
Why?
| | DNA Mutational Analysis | 4 | 2019 | 372 | 0.220 |
Why?
| | RNA, Messenger | 1 | 2010 | 2558 | 0.220 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 954 | 0.220 |
Why?
| | Disease Management | 4 | 2021 | 563 | 0.210 |
Why?
| | Uncertainty | 1 | 2023 | 95 | 0.210 |
Why?
| | Antibodies, Neoplasm | 3 | 2007 | 30 | 0.210 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2022 | 46 | 0.210 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 82 | 0.210 |
Why?
| | Disease Progression | 3 | 2023 | 2392 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2022 | 115 | 0.210 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.210 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 71 | 0.200 |
Why?
| | Hematology | 1 | 2022 | 13 | 0.200 |
Why?
| | Thalidomide | 2 | 2012 | 28 | 0.200 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 10 | 0.200 |
Why?
| | Myeloproliferative Disorders | 1 | 2022 | 26 | 0.200 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 42 | 0.200 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 41 | 0.200 |
Why?
| | Receptors, Mitogen | 1 | 2021 | 8 | 0.190 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 995 | 0.190 |
Why?
| | Lectins, C-Type | 1 | 2021 | 61 | 0.190 |
Why?
| | Erythroblasts | 1 | 2020 | 12 | 0.180 |
Why?
| | Blood Cell Count | 1 | 2020 | 52 | 0.180 |
Why?
| | Lipase | 1 | 2020 | 57 | 0.180 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 174 | 0.180 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 312 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2020 | 476 | 0.170 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 118 | 0.170 |
Why?
| | Dendritic Cells | 1 | 2023 | 436 | 0.170 |
Why?
| | Tumor Lysis Syndrome | 1 | 2019 | 7 | 0.170 |
Why?
| | Immunoconjugates | 1 | 2021 | 87 | 0.170 |
Why?
| | United States | 5 | 2023 | 12209 | 0.170 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2021 | 125 | 0.170 |
Why?
| | Age Factors | 5 | 2022 | 2891 | 0.170 |
Why?
| | Genomics | 3 | 2019 | 641 | 0.170 |
Why?
| | Fatty Acids | 2 | 2020 | 382 | 0.170 |
Why?
| | Genetic Testing | 2 | 2019 | 379 | 0.170 |
Why?
| | Leukopoiesis | 1 | 2019 | 10 | 0.160 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 15 | 0.160 |
Why?
| | Mycoses | 1 | 2019 | 66 | 0.160 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 42 | 0.160 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2019 | 25 | 0.160 |
Why?
| | RAW 264.7 Cells | 1 | 2019 | 41 | 0.160 |
Why?
| | K562 Cells | 1 | 2019 | 73 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 447 | 0.160 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 10 | 0.160 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 15 | 0.160 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 219 | 0.160 |
Why?
| | Antibodies | 1 | 2021 | 372 | 0.160 |
Why?
| | Hematologic Diseases | 1 | 2019 | 57 | 0.160 |
Why?
| | Amino Acids | 2 | 2020 | 449 | 0.160 |
Why?
| | Antibiotic Prophylaxis | 1 | 2019 | 96 | 0.160 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 82 | 0.160 |
Why?
| | Lymphoma | 2 | 2017 | 177 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1215 | 0.150 |
Why?
| | Trees | 1 | 2018 | 61 | 0.150 |
Why?
| | Cysteine | 1 | 2019 | 171 | 0.150 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 61 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 32 | 0.140 |
Why?
| | Confidence Intervals | 1 | 2018 | 309 | 0.140 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 220 | 0.140 |
Why?
| | Hematinics | 1 | 2017 | 18 | 0.140 |
Why?
| | Cohort Studies | 5 | 2022 | 4903 | 0.140 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 175 | 0.140 |
Why?
| | Energy Metabolism | 2 | 2019 | 724 | 0.140 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 372 | 0.140 |
Why?
| | Periodicals as Topic | 1 | 2019 | 181 | 0.140 |
Why?
| | Hedgehog Proteins | 1 | 2018 | 173 | 0.140 |
Why?
| | Pyrimidines | 2 | 2017 | 378 | 0.140 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 63 | 0.140 |
Why?
| | Genome, Human | 1 | 2018 | 352 | 0.140 |
Why?
| | Biomarkers | 3 | 2022 | 3418 | 0.140 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 37 | 0.140 |
Why?
| | Unrelated Donors | 1 | 2016 | 38 | 0.130 |
Why?
| | Geriatric Assessment | 1 | 2018 | 176 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2017 | 292 | 0.130 |
Why?
| | Nitriles | 1 | 2017 | 151 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2023 | 802 | 0.130 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 71 | 0.130 |
Why?
| | Oncogene Proteins | 1 | 2016 | 53 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2102 | 0.130 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 817 | 0.130 |
Why?
| | Mice, Inbred NOD | 4 | 2019 | 561 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 195 | 0.130 |
Why?
| | Methyltransferases | 1 | 2016 | 61 | 0.130 |
Why?
| | Mitochondria | 2 | 2018 | 751 | 0.130 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 13 | 0.130 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 62 | 0.130 |
Why?
| | Hemoglobins | 2 | 2018 | 314 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 138 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1749 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 8 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 17 | 0.120 |
Why?
| | Homeostasis | 1 | 2018 | 576 | 0.120 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 95 | 0.120 |
Why?
| | Cell Survival | 4 | 2022 | 1022 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 314 | 0.120 |
Why?
| | Necrosis | 1 | 2015 | 210 | 0.120 |
Why?
| | Adolescent | 6 | 2019 | 17826 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1801 | 0.120 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 58 | 0.120 |
Why?
| | Cells, Cultured | 5 | 2019 | 3897 | 0.110 |
Why?
| | Vidarabine | 2 | 2018 | 26 | 0.110 |
Why?
| | Phenotype | 2 | 2019 | 2817 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 282 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1523 | 0.110 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.110 |
Why?
| | Registries | 2 | 2023 | 1760 | 0.110 |
Why?
| | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2013 | 1 | 0.110 |
Why?
| | Glucose | 1 | 2018 | 897 | 0.110 |
Why?
| | Alemtuzumab | 3 | 2007 | 12 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1148 | 0.110 |
Why?
| | Carbon Monoxide | 1 | 2013 | 65 | 0.110 |
Why?
| | Pyridazines | 1 | 2013 | 49 | 0.110 |
Why?
| | Liver | 1 | 2020 | 1634 | 0.110 |
Why?
| | Interleukin-1 | 1 | 2017 | 966 | 0.100 |
Why?
| | Nausea | 1 | 2012 | 104 | 0.100 |
Why?
| | 5-Methylcytosine | 1 | 2012 | 16 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2018 | 1022 | 0.100 |
Why?
| | Vomiting | 1 | 2012 | 124 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1045 | 0.100 |
Why?
| | Imidazoles | 1 | 2013 | 211 | 0.100 |
Why?
| | Length of Stay | 1 | 2016 | 949 | 0.100 |
Why?
| | Incidence | 2 | 2016 | 2316 | 0.100 |
Why?
| | Software | 1 | 2015 | 537 | 0.100 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 31 | 0.090 |
Why?
| | Fatigue | 1 | 2012 | 296 | 0.090 |
Why?
| | Cell Line, Tumor | 5 | 2018 | 2725 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 1988 | 0.090 |
Why?
| | Dioxygenases | 1 | 2010 | 25 | 0.090 |
Why?
| | Sesquiterpenes | 2 | 2016 | 51 | 0.090 |
Why?
| | Ethanol | 1 | 2015 | 548 | 0.090 |
Why?
| | Insulin Resistance | 1 | 2018 | 1072 | 0.090 |
Why?
| | Chronic Disease | 1 | 2016 | 1593 | 0.090 |
Why?
| | Oxidants | 1 | 2011 | 112 | 0.090 |
Why?
| | GTP-Binding Proteins | 1 | 2011 | 139 | 0.090 |
Why?
| | Wasp Venoms | 1 | 2009 | 4 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2011 | 159 | 0.090 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 134 | 0.080 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 287 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2023 | 1953 | 0.080 |
Why?
| | Emergencies | 1 | 2009 | 146 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 206 | 0.080 |
Why?
| | Immunization Schedule | 1 | 2010 | 184 | 0.080 |
Why?
| | Epinephrine | 1 | 2009 | 167 | 0.080 |
Why?
| | RNA, Small Interfering | 3 | 2016 | 543 | 0.080 |
Why?
| | Inflammation | 1 | 2019 | 2485 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 4718 | 0.080 |
Why?
| | Melphalan | 1 | 2007 | 29 | 0.070 |
Why?
| | Blood Transfusion | 2 | 2020 | 276 | 0.070 |
Why?
| | Transplantation Chimera | 1 | 2007 | 51 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2022 | 855 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2019 | 591 | 0.070 |
Why?
| | Karnofsky Performance Status | 1 | 2006 | 36 | 0.070 |
Why?
| | Receptors, Thrombopoietin | 2 | 2016 | 5 | 0.070 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 399 | 0.070 |
Why?
| | Exome | 2 | 2018 | 201 | 0.070 |
Why?
| | Calreticulin | 2 | 2016 | 24 | 0.070 |
Why?
| | Janus Kinase 2 | 2 | 2016 | 31 | 0.070 |
Why?
| | Ganciclovir | 1 | 2006 | 49 | 0.070 |
Why?
| | Risk Factors | 3 | 2014 | 8637 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 675 | 0.070 |
Why?
| | Risk Assessment | 3 | 2021 | 2975 | 0.070 |
Why?
| | Valine | 1 | 2006 | 72 | 0.060 |
Why?
| | Acyclovir | 1 | 2006 | 100 | 0.060 |
Why?
| | Cell Proliferation | 3 | 2020 | 2199 | 0.060 |
Why?
| | Philadelphia Chromosome | 2 | 2016 | 15 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 241 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 927 | 0.060 |
Why?
| | Pedigree | 2 | 2015 | 467 | 0.060 |
Why?
| | Janus Kinases | 2 | 2015 | 12 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2015 | 1870 | 0.060 |
Why?
| | Cytomegalovirus Infections | 1 | 2006 | 183 | 0.060 |
Why?
| | Diamines | 1 | 2023 | 3 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 706 | 0.060 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | Flow Cytometry | 2 | 2018 | 1087 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 130 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1400 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 215 | 0.050 |
Why?
| | Neutropenia | 1 | 2022 | 125 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 347 | 0.050 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 14 | 0.050 |
Why?
| | Quinuclidines | 1 | 2020 | 4 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2020 | 59 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2022 | 354 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2006 | 647 | 0.040 |
Why?
| | Hyperbilirubinemia | 1 | 2020 | 14 | 0.040 |
Why?
| | Niacinamide | 1 | 2020 | 64 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1080 | 0.040 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 94 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 250 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 45 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2016 | 2586 | 0.040 |
Why?
| | Iron | 1 | 2020 | 233 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 635 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| | Daunorubicin | 1 | 2018 | 24 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2018 | 9 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 184 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3549 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 320 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 270 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| | Cause of Death | 1 | 2020 | 363 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 268 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 98 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 171 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 73 | 0.040 |
Why?
| | HLA Antigens | 1 | 2019 | 224 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 434 | 0.040 |
Why?
| | Glutathione | 1 | 2019 | 300 | 0.040 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 12 | 0.040 |
Why?
| | Biological Transport | 1 | 2018 | 372 | 0.040 |
Why?
| | Cell Count | 1 | 2018 | 305 | 0.040 |
Why?
| | Glycolysis | 1 | 2018 | 227 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1126 | 0.040 |
Why?
| | Tumor Stem Cell Assay | 1 | 2017 | 33 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2018 | 225 | 0.040 |
Why?
| | Retinal Dehydrogenase | 1 | 2017 | 41 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2023 | 765 | 0.040 |
Why?
| | Transcriptome | 1 | 2022 | 728 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 431 | 0.030 |
Why?
| | Arsenicals | 1 | 2017 | 24 | 0.030 |
Why?
| | Oxides | 1 | 2017 | 43 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 28 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 33 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 536 | 0.030 |
Why?
| | NADP | 1 | 2016 | 43 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 117 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2017 | 217 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 43 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 286 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 12 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 390 | 0.030 |
Why?
| | Kinetics | 1 | 2019 | 1555 | 0.030 |
Why?
| | Sample Size | 1 | 2016 | 114 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 262 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 227 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 265 | 0.030 |
Why?
| | Quality of Life | 2 | 2016 | 2359 | 0.030 |
Why?
| | Isoenzymes | 1 | 2016 | 285 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 283 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 446 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2018 | 368 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 330 | 0.030 |
Why?
| | Comorbidity | 2 | 2013 | 1458 | 0.030 |
Why?
| | Splenomegaly | 1 | 2015 | 17 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 181 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1699 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 350 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1355 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2015 | 30 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 396 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 63 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 370 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2017 | 221 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 353 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 448 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 46 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 932 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 214 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2015 | 503 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 49 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 110 | 0.030 |
Why?
| | Cyclosporine | 1 | 2014 | 161 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 316 | 0.030 |
Why?
| | Leukemia, Lymphoid | 1 | 2013 | 27 | 0.030 |
Why?
| | Trans-Activators | 1 | 2016 | 368 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 812 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 60 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 437 | 0.030 |
Why?
| | Phosphorylation | 1 | 2017 | 1572 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1893 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1152 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 464 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 546 | 0.030 |
Why?
| | Thrombosis | 1 | 2015 | 297 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 524 | 0.020 |
Why?
| | Leupeptins | 1 | 2011 | 10 | 0.020 |
Why?
| | Child | 1 | 2010 | 18362 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2011 | 28 | 0.020 |
Why?
| | Blast Crisis | 1 | 2011 | 20 | 0.020 |
Why?
| | Prospective Studies | 2 | 2016 | 6218 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2011 | 45 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 40 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2010 | 12 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 78 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1775 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2251 | 0.020 |
Why?
| | Etoposide | 1 | 2010 | 148 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 134 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2791 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2011 | 152 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2011 | 142 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 345 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1630 | 0.020 |
Why?
| | Treatment Failure | 1 | 2010 | 332 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2079 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 344 | 0.020 |
Why?
| | Nitroimidazoles | 1 | 2004 | 6 | 0.010 |
Why?
| | Cyclohexanes | 1 | 2004 | 22 | 0.010 |
Why?
| | Fluorescein | 1 | 2004 | 26 | 0.010 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 119 | 0.010 |
Why?
| | Lectins | 1 | 2004 | 44 | 0.010 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2004 | 38 | 0.010 |
Why?
| | Capillaries | 1 | 2004 | 91 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2004 | 232 | 0.010 |
Why?
| | Microcirculation | 1 | 2004 | 135 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 293 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 109 | 0.010 |
Why?
| | Angiography | 1 | 2004 | 176 | 0.010 |
Why?
| | Wilms Tumor | 1 | 2004 | 69 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 283 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 499 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1635 | 0.010 |
Why?
| | Hypoxia | 1 | 2004 | 960 | 0.010 |
Why?
|
|
Pollyea's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|